Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS
March 3, 2023
Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 5, 2023
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
November 15, 2022
Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
BOSTON, Mass., and SEATTLE, Wash. – November 7, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. “Patients are the central […]
Affini-T Therapeutics Named to the 2022 Endpoints 11
BOSTON, Mass., and SEATTLE, Wash. – September 22, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has been selected by Endpoints News Editor John Carroll as one of the most promising startups in biotech for his annual report on the Endpoints 11. “We are honored […]
Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer
Dr. Nagorsen brings over two decades of leadership in oncology, most recently at Amgen where he led the early development of Lumakras® and Blincyto® BOSTON, Mass., and SEATTLE, Wash. – July 26, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment […]
Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors
BOSTON, Mass., and SEATTLE, Wash. – July 12, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Jill DeSimone to its board of directors. Ms. DeSimone brings more than 40 years of global business expertise in life sciences to Affini-T’s board. […]
Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients
BOSTON, Mass., and SEATTLE, Wash., and EMERYVILLE, Calif., June 15th, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex […]
Affini-T Therapeutics to Present at Upcoming Investor and Industry Conferences
BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced three presentations at upcoming investor and industry conferences. Jak Knowles, M.D., Co-founder, President and Chief Executive Officer of Affini-T Therapeutics, will present at each discussing the company’s T cell receptor (TCR) discovery platform, lead […]
Clinical Strategy for Enhancing Affini-T Therapeutics’ Merkel Polyoma Virus TCR Therapy to be Presented at ASCO 2022
BOSTON, Mass., and SEATTLE, Wash. – June 2, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that the clinical strategy for enhancing the efficacy of its Merkel cell polyomavirus (MCPyV)-specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC), from […]
